The FAST Global Summit & Gala draws more than 1,000 attendees from around the world. The annual event features a science summit, an education summit and an AAC carnival, and the weekend concludes with a star-studded gala recognized as Chicago’s largest celebrity fundraiser. Scroll down and click on the links below to watch presentations from the 2017 Summit, and remember to mark your calendar for the 2018 Summit, which kicks off Dec. 7.
FAST Science Summit [bookmark id=»science-summit»]
FAST’s Science Summit provides an opportunity to interact directly with the scientists, researchers, and pharmaceutical and biotechnology company leaders working on a cure for Angelman syndrome, while getting up to speed on all of the latest developments and breakthroughs in AS research.
AAV-mediated gene therapy to the central nervous system: prospect for Angelman syndrome
James M. Wilson, M.D., Ph.D., Rose H. Weiss professor and director, Orphan Disease Center; director, Gene Therapy Program, Perelman School of Medicine, University of Pennsylvania
Gene therapy round table: ask the experts
Arthur L. Beaudet, M.D., Baylor College of Medicine
Scott Dindot, Ph.D., Texas A&M University
Kevin Nash, Ph.D., University of South Florida
David Segal, Ph.D., University of California, Davis
Edwin Weeber. Ph.D., University of South Florida
James M. Wilson, M.D., Ph.D., Penn Medicine’s Orphan Disease Center
Ashley Winslow, Ph.D., Penn Medicine’s Orphan Disease Center
Overview of the FAST research agenda for gene therapy and genetic editing in Angelman syndrome
Allyson Berent, DVM, DACVIM, chief science officer, FAST
The Global Angelman Syndrome Registry
Megan Cross, chair, FAST Australia
Chloe Simons, chief science officer, FAST Australia
Modifying the Bayley test to benefit clinical trials in Angelman syndrome
Anjali Sadhwani, Ph.D., clinical psychologist, Boston Children’s Hospital
Anne Wheeler, Ph.D., public health researcher, RTI International
Meagan Miller, Ph.D., discovery project leader, Roche
In the clinic: Ovid Therapeutics-OV101 and the engagement with the Angelman community
Jeremy Levin, D.Phil., MB BChir, chairman and chief executive officer, Ovid Therapeutics Inc.
Amit Rakhit M.D., MBA, chief medical and portfolio officer, Ovid Therapeutics Inc.
Approaching the clinic: nutritional support for patients with Angelman syndrome
Mike McCandless, founder, Disruptive Nutrition
Jessica Duis, M.D., M.S., assistant professor of pediatrics, Vanderbilt University Medical Center
Donna Herber, Ph.D., chief science officer, Disruptive Nutrition
AAV-mediated gene therapy approach: Ovid Therapeutics
Ed Weeber, Ph.D., Ph.D., professor, University of South Florida
Jenn Daley, Ph.D., director of research, Agilis Biotherapeutics
The Angelman Biomarkers and Outcome Measures Alliance (A-BOM)
Terry Jo Bichell, Ph.D., director, Angelman Biomarkers and Outcome Measures Alliance
Education Summit [bookmark id=»education-summit»]
The Education Summit provide parents, caregivers, therapists and educators with product demonstrations and information about services that can help improve the quality of life for individuals with Angelman syndrome – and those who care for them.
Introduction to augmentative and alternative communication (AAC)
Kelly Fonner, M.S., educational assistive technology trainer and consultant
Reading and writing in Angelman syndrome
Kelly Fonner, M.S., educational assistive technology trainer and consultant
Nancy Robinson, Ph.D., Communicative Disorders Program, San Francisco State University
Kathleen Sadao, Ed.D., educational consultant
Kate Ahern, M.S.Ed.
Kelly Fonner, M.S.
Nancy Robinson, Ph.D.
Kathleen Sadao, Ed.D.
Prentke Romich Company (PRC), Saltillo and Tobii-Dynavox
Understanding anxiety and challenging behaviors in Angelman syndrome
Kate Ahern, M.S.Ed., assistive technology specialist
Kate Ahern, M.S.
Shibvon Sargent, parent
Implementing strategies in the school placement panel
Amy Girouard, parent
Shari Holt, MHS, CCC-SLP
Danielle Williams, B.A., LBS1
Trish Brawley, B.A., LBS1